fashion -WSS

fashion

author：Wikipedia 2025-09-29 21:27:11 - browse：88641

Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion consumer health division, which is exploring over-the-counter moves for the erectile dysfunction drug Cialis and the flu treatment Tamiflu.

Investors reacted swiftly, bidding Sanofi’s American depository receipts on the New York Stock Exchange down nearly 18% to less than $44 in morning trading. Jared Holz, an analyst at Mizuho, warned investors that the drop “would be the largest negative single-day stock move across Global Pharma in more than ten years.”

It would be tempting to take the stock move as evidence that investors have finally tired of watching drug companies treat consumer product divisions like baseball trading cards, buying them at a high price only to sell them again a decade later. But the move probably has little to do with the current passion for pharma spinouts or with Sanofi following in the footsteps of GSK, Novartis, and Pfizer in shedding a division. Or even, for that matter, Sanofi, which shed its pharmaceutical ingredients business, EuroAPI, which is now trading at a third of its initial public offering price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： How climate

explore

WSS

Pharmacists can make shortage drugs, but at what cost?

In areas with more Black doctors, Black people live longer

Why we need to separate burnout from moral injury in health care

The explosion of genetic testing requires a new approach

Ask STAT: What do you want to know about ChatGPT in medicine?

Medicare reduced heart disease by changing how it pays doctors

Wikipedia

fashion

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Gene therapy has helped boys walk. Can scientists keep it that way?

As demand for Covid shots wanes, Moderna seeks its next success

With FDA staff opposed to Sarepta therapy, top official intervened

Tori Bowie and the unacceptable rates of Black maternal death

Senate committee scrutinizes Medicare Advantage brokers

Wildfire smoke exposes gaps in outdoor worker protections

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Anesthesiologist group: stop taking Ozempic before surgery

Pharmacists can make shortage drugs, but at what cost?

hotspot

FDA gives detailed accounting of AI

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

How climate

Researchers explore possible ties between long Covid, menopause

2023 STAT Wunderkinds: get to know the winners

entertainment

explore

knowledge

explore